Last reviewed · How we verify
Iophendylate (iofendylate)
Iophendylate (generic name: iofendylate) is a iofendylate drug developed by Novartis. It is currently FDA-approved.
Iophendylate is a small molecule with synonyms including Iofendylate, used as a radiocontrast agent. It was historically used for myelography studies, marketed under trade names such as Pantopaque and Myodil.
At a glance
| Generic name | iofendylate |
|---|---|
| Sponsor | Novartis |
| Drug class | iofendylate |
| Therapeutic area | Neuroscience |
| Phase | FDA-approved |
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Iophendylate CI brief — competitive landscape report
- Iophendylate updates RSS · CI watch RSS
- Novartis portfolio CI
Frequently asked questions about Iophendylate
What is Iophendylate?
Iophendylate (iofendylate) is a iofendylate drug developed by Novartis.
Who makes Iophendylate?
Iophendylate is developed and marketed by Novartis (see full Novartis pipeline at /company/novartis).
What is the generic name of Iophendylate?
iofendylate is the generic (nonproprietary) name of Iophendylate.
What drug class is Iophendylate in?
Iophendylate belongs to the iofendylate class. See all iofendylate drugs at /class/iofendylate.
What development phase is Iophendylate in?
Iophendylate is FDA-approved (marketed).
Related
- Drug class: All iofendylate drugs
- Manufacturer: Novartis — full pipeline
- Therapeutic area: All drugs in Neuroscience
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing